Seminars in Oncology
Volume 36, Issue 3 , Pages 258-274 , June 2009

Thyroid Cancer in Young Adults

  • Anita K. Ying

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • Division of Pediatrics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Winston Huh

      Affiliations

    • Division of Pediatrics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Sarah Bottomley

      Affiliations

    • Division of Pediatrics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Douglas B. Evans

      Affiliations

    • Department of Surgical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Steven G. Waguespack

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, TX
    • Division of Pediatrics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress correspondence to Steven G. Waguespack, MD, Department of Endocrine Neoplasia and Hormonal Disorders, PO Box 301402, Unit 1461, Houston TX 77230-1402

References 

  1. American Cancer Society. Cancer facts & figures 2008. Atlanta, GA: American Cancer Society; 2008;
  2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2004 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. www.cdc.gov/uscs2008;
  3. In:  Ries L,  Melbert D,  Krapcho M, et al. editor. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008;Available at: http://seer.cancer.gov/csr/1975_2005/
  4. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–511
  5. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999;16:64–69
  6. Kim TY, Kim KW, Jung TS, Kim JM, Kim SW, Chung KW, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck. 2007;29:765–772
  7. Kosary C. Cancer of the Thyroid. in Ries LAG YJ In:  Keel GE,  Eisner MP,  Lin YD,  Horner MJ editor. SEER Survival Monograph: Cancer Survival Among Adults: U.S. Seer Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute; 2007;p. 217–226
  8. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:525–538
  9. Waguespack S, Wells S, Ross J, Bleyer A. Thyroid cancer. In:  Bleyer A,  O'Leary M,  Barr R, et al. editor. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival 1975-2000. Bethesda, MD: National Cancer Institute; 2006;p. 143–154
  10. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–378
  11. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, et al. Recent advances in thyroid cancer. Curr Probl Surg. 2008;45:156–250
  12. Shaha AR. TNM classification of thyroid carcinoma. World J Surg. 2007;31:879–887
  13. AACE/AAES medical/surgical guidelines for clinical practice. management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001;7:202–220
  14. British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer. London: Royal College of Physicians; 2007;
  15. Sherman SI, et al. NCCN thyroid carcinoma clinical practice guidelines in oncology (v.1.2008). Ft. Washington, PA: National Comprehensive Cancer Network; 2008;Available at: http://www.nccn.org
  16. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–5671
  17. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  18. Schlumberger M, Pacini F. Thyroid tumors. Paris: Nucleon; 2003;
  19. Schneider AB. Radiation-induced thyroid cancer (UpToDate Online 16.2). 2007 www.uptodate.com
  20. Boice JD. Cancer following irradiation in childhood and adolescence. Med Pediatr Oncol Suppl. 1996;1:29–34
  21. Samaan NA, Schultz PN, Ordonez NG, Hickey RC, Johnston DA. A comparison of thyroid carcinoma in those who have and have not had head and neck irradiation in childhood. J Clin Endocrinol Metab. 1987;64:219–223
  22. Acharya S, Sarafoglou K, LaQuaglia M, Lindsley S, Gerald W, Wollner N, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003;97:2397–2403
  23. Shibata Y, Yamashita S, Masyakin VB, Panasyuk GD, Nagataki S. 15 years after Chernobyl: new evidence of thyroid cancer. Lancet. 2001;358:1965–1966
  24. Merchant TE, Williams T, Smith JM, Rose SR, Danish RK, Burghen GA, et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys. 2002;54:45–50
  25. Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, Preto A, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:333–362
  26. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(Suppl 2):S37–S43
  27. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003;195:168–186
  28. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–6379
  29. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93:1600–1608
  30. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am. 2008;37:375–387
  31. Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg. 2008;32:678–682
  32. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? (A multicenter series). Surgery. 2000;128:1043–1051
  33. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol. 1999;16:16–18
  34. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15:1075–1081
  35. Cavaco BM, Batista PF, Martins C, Banito A, do Rosario F, Limbert E, et al. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer. 2008;15:207–215
  36. Uchino S, Noguchi S, Yamashita H, Watanabe S, Ogawa T, Tsuno A, et al. Mutational analysis of the APC gene in cribriform-morula variant of papillary thyroid carcinoma. World J Surg. 2006;30:775–779
  37. Patel SG, Escrig M, Shaha AR, Singh B, Shah JP. Management of well-differentiated thyroid carcinoma presenting within a thyroglossal duct cyst. J Surg Oncol. 2002;79:134–139
  38. Salvatori M, Saletnich I, Rufini V, Dottorini ME, Corsello SM, Troncone L, et al. Severe thyrotoxicosis due to functioning pulmonary metastases of well-differentiated thyroid cancer. J Nucl Med. 1998;39:1202–1207
  39. Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma (A clinicopathologic study of 105 consecutive patients). Cancer. 1992;70:1585–1590
  40. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–954
  41. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer. 1993;71:1348–1352
  42. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–381
  43. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with “berry picking” than neck dissection in thyroid cancer. Am Surg. 2003;69:191–196
  44. Kupferman ME, Patterson DM, Mandel SJ, LiVolsi V, Weber RS. Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope. 2004;114:403–406
  45. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–330
  46. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622–627
  47. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  48. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899
  49. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–1242
  50. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764–770
  51. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–932
  52. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–1591
  53. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:497–509
  54. Sheils OM, Sweeney EC. TSH receptor status of thyroid neoplasms—TaqMan RT-PCR analysis of archival material. J Pathol. 1999;188:87–92
  55. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318–4323
  56. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554–564
  57. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1:32–40
  58. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007;92:3–9
  59. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–1127
  60. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139:346–351
  61. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  62. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–5057
  63. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93:76–81
  64. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499–1501
  65. Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:1519–1525
  66. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498–505
  67. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol. 2003;76:690–695
  68. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148–156
  69. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66:8715–8721
  70. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:2369–2376
  71. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008;37:511–524
  72. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–4719
  73. Kloos R, Ringel M, Knopp M, Heverhagen J, Rittenberry J, Weldy L, et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study. J Clin Oncol. 2006;24:5534
  74. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–4713
  75. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008;19:547–552
  76. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–2142
  77. Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008;37:481–496
  78. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–687
  79. Machens A. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2004;350:943
  80. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–856
  81. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460
  82. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994;91:1579–1583
  83. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880–887
  84. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134:890–899
  85. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305–310
  86. Fife KM, Bower M, Harmer CL. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol. 1996;22:588–591
  87. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, et al. Postoperative radiotherapy for advanced medullary thyroid cancer—local disease control in the modern era. Head Neck. 2008;30:883–888
  88. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077–6084
  89. Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239–246
  90. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–4190
  91. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol. 2005;89:122–129
  92. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466–3469
  93. Frank K, Raue F, Gottswinter J, Heinrich U, Meybier H, Ziegler R. Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). Eur J Pediatr. 1984;143:112–116
  94. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25:6018
  95. Schlumberger M, Elise R, Sherman SI, et al. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer (Presented at 89th Annual Meeting of the Endocrine Society). June 2007;Toronto, Canada
  96. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–323
  97. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25:14065
  98. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008;7:1001–1006
  99. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med. 2008;148:567
  100. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26:3522
  101. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California Cancer Registry. Am J Obstet Gynecol. 2003;189:1128–1135
  102. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997;82:2862–2866
  103. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92:S1–S47
  104. Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B, et al. Thyroid cancer in pregnancy. Int J Gynaecol Obstet. 2005;91:15–20
  105. Thomas AK, McVie R, Levine SN. Disorders of maternal calcium metabolism implicated by abnormal calcium metabolism in the neonate. Am J Perinatol. 1999;16:515–520
  106. Leboeuf R, Emerick LE, Martorella AJ, Tuttle RM. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid. 2007;17:543–547
  107. Rosario PW, Barroso AL, Purisch S. The effect of subsequent pregnancy on patients with thyroid carcinoma apparently free of the disease. Thyroid. 2007;17:1175–1176
  108. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351:241–249
  109. Kamari Y, Sharabi Y, Leiba A, Peleg E, Apter S, Grossman E. Peripartum hypertension from pheochromocytoma: a rare and challenging entity. Am J Hypertens. 2005;18:1306–1312
  110. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;69:479–490
  111. Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;68:610–617
  112. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  113. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbe M, Ceccarelli C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med. 2008;49:845–852
  114. van Santen HM, Aronson DC, Vulsma T, Tummers RF, Geenen MM, de Vijlder JJ, et al. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur J Cancer. 2004;40:1743–1751
  115. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck. 2003;25:349–356
  116. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002;43:856–861
  117. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265–271
  118. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?. J Nucl Med. 2005;46:261–266
  119. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17:1277–1288
  120. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504–515
  121. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol. 2006;163:521–527
  122. Zarnegar R, Brunaud L, Clark OH. Prevention, evaluation, and management of complications following thyroidectomy for thyroid carcinoma. Endocrinol Metab Clin North Am. 2003;32:483–502
  123. Roh JL, Yoon YH, Park CI. Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: evaluation and management of resulting vocal dysfunction. Am J Surg. 2008;Epub ahead of print
  124. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77:334–338
  125. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000;85:159–164
  126. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab. 1997;82:2592–2595
  127. Padayatty S. Concerning minimal cardiac effects in asymptomatic athyreotic patients treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab. 1998;83:2607–2608
  128. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid. 2004;14:133–140
  129. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab. 2005;90:4946–4954
  130. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bax JJ, Romijn JA, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf). 2006;64:284–291
  131. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42
  132. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215–220

PII: S0093-7754(09)00045-1

doi: 10.1053/j.seminoncol.2009.03.009

Seminars in Oncology
Volume 36, Issue 3 , Pages 258-274 , June 2009

Article Tools

* Image Usage & Resolution